

The role of the osteoclast during endochondral  
ossification in a rat fracture model

Michelle Maree McDonald

Submitted for the degree of  
Doctor of Philosophy

The Orthopaedic Research and Biotechnology  
Department, The Children's Hospital Westmead

The University of Technology Sydney

May 2007



## Certificate of authorship

I certify that the work in this thesis has not previously been submitted for a degree nor has it been submitted as part of requirements for a degree as fully acknowledged within the text.

I also certify that the thesis has been written by me, any help that I have received in my research work and the preparation of the thesis itself has been acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis.

Signature of Candidate

## Acknowledgements and Dedication

Many people have contributed to this thesis. Principal amongst these is my mentor and co-supervisor Associate Professor David Little, without whom this thesis may never have been completed. His scientific insight, encouragement and commitment to the project have been inspirational. Professor Little has provided extensive support and advice above and beyond that expected of a mentor or supervisor. My gratitude towards Professor Little extends beyond a debt that could ever be repaid. I am extremely thankful for his consistent belief in me. He has instilled in me a desire to continue learning and exploring the world of science that I would have never imagined possible.

I would like to thank my principal supervisor Dr Tamara Sztynka for her patience, support and infinite advice over the past 4 years. Dr Sztynka has motivated me to rise to each challenge I have faced. Her enthusiasm for research is inspiring and her implausible attention to detail has left a great impression on me. Dr Sztynka is a teacher with no boundaries whom I have enjoyed learning from for many years. I aspire to teach others in the future half as well as she does.

The Children's Hospital at Westmead has provided me with all the necessary infrastructure support to complete my experimental work and I am extremely grateful to the institute. My colleagues here have been a valuable support system; in particular I would like to thank Dr Aaron Schindeler, for his patience and guidance when teaching a typical histologist about the world of cell culture and for instilling some of his extensive knowledge on scientific writing in me. To Dr Negin Amanat, thank you for all your engineering expertise and perseverance when teaching me. To the lab staff, thank you all for your friendly words of support. In particular, I would like to thank Kathy Mikulec and Alyson Morse and Helen Chapman for their extremely competent technical help which allowed me to focus and complete this enormous task. To Rachel Peat for assisting with the completion of this thesis and friendly advice.

The Mechanical Engineering department at Sydney University provided the equipment that allowed me to perform mechanical testing, and the Electron Microscopy unit provided access to microCT equipment for analysis. Staff from the Bone Program at the Garvan Institute, were also instrumental in supporting this work. Finally, the staff at the Institute of Medical and Veterinary Science in Adelaide assisted this work by performing some back scatter electron analysis on my samples.

To my parents, family and friends, I would like to express my gratitude to you all for your eternal belief in me and encouragement to keep at it, even when times got very hard. I finally finished my book and in doing so I've proven my nerd status in the family.

## Acknowledgements and dedication

To my fiancé Paul, you are the reason I continue to push myself to climb mountains in life, I know you will always be behind me to catch me if I fall. Thank you for opening my mind and heart to a life of endless possibilities.

Finally, to my two loving grandmothers, Grandma Morris, who passed away in January 2006 and Nan O'Donnell, who passed on in February 2007. I know you will be smiling down on me with the pride and love that only Grandmothers know. Thank you for believing in me, to you both I dedicate this, the first PhD thesis in the families.

## Table of contents

Certificate of authorship .....	I
Acknowledgements .....	II
Table of contents .....	III-VII
List of Illustrations .....	VII-XII
Abbreviations .....	XII-XVI
Abstract .....	XVII
Chapter 1 Introduction .....	1
1.1 Bone Biology.....	1
1.1.1 Background.....	1
1.2 Development and regulation at the growth plate .....	2
1.2.1 Long bone and physis formation.....	2
1.2.2 Chondrocyte development and maturation .....	3
1.2.3 Paracrine regulation of the growth plate .....	5
1.2.4 Growth cartilage calcification .....	7
1.2.5 Vascularisation of calcified cartilage.....	8
1.2.5.1 Early theories of vascularisation .....	8
1.2.6 Recent theories - Growth factors and angiogenesis .....	10
1.2.6.1 Vascular endothelial growth factor.....	10
1.2.6.2 Matrix metalloproteinase's (MMPs).....	10
1.2.6.3 The current understanding of the activity of osteoclasts and chondroclasts at the chondro-osseous junction.....	14
1.2.6.4 Elimination of osteoclast/chondroclast activity from the vascularisation of chondral matrix.....	15
1.3 The mechanism of endochondral fracture repair .....	17
1.3.1 General overview .....	17
1.3.2 Growth plate processes are recapitulated during fracture healing.....	18
1.3.2.1 Paracrine regulation.....	18
1.3.2.2 Matrix metalloproteinase (MMP) activity .....	20
1.3.2.3 Angiogenesis .....	22
1.3.2.4 Hard callus remodelling requires osteoclastic resorption.....	25
1.3.3 Animal models of fracture repair .....	26
1.4 Osteoclast activity during skeletal growth and repair.....	27
1.4.1 The cell biology of the osteoclast.....	27
1.4.2 Regulation of osteoclast formation and activity.....	32
1.4.3 The role of the osteoclast in bone growth and remodelling .....	34
1.4.4 The role of the osteoclast in bone repair.....	35
1.4.5 Animal models of defective osteoclastogenesis .....	37
1.4.5.1 Animal models of osteoclast dysfunction .....	38
1.4.6 The incisor absent ( <i>ia/ia</i> ) rat .....	47
1.4.6.1 Bone phenotype in the <i>ia/ia</i> rat .....	47
1.4.6.2 Osteoclast function in the <i>ia/ia</i> rat.....	49
1.4.6.3 Fracture repair in the <i>ia/ia</i> rat.....	51
1.4.7 Pharmacological inhibition of osteoclast formation and activity .....	53
1.4.7.1 Recombinant OPG .....	53
1.4.7.2 Cathepsin K inhibitor.....	53
1.4.7.3 RANK:Fc .....	54
1.4.7.4 RANKL inhibition (Denosumab).....	55
1.4.7.5 Bisphosphonates .....	55

## Table of Contents

1.5	Bisphosphonates .....	55
1.5.1	Mechanisms of bisphosphonate action .....	55
1.5.2	Bisphosphonates for the treatment of osteoporosis.....	57
1.5.2.1	Bisphosphonates and mineralisation of bone .....	58
1.5.2.2	Potential complications of bisphosphonate therapy.....	59
1.5.2.3	Regimen options for bisphosphonate treatment .....	59
1.5.3	Bisphosphonates and fracture repair .....	60
1.5.4	Bisphosphonates and bone growth.....	64
1.5.5	Zoledronic acid and fracture repair .....	65
1.5.6	Bisphosphonate dosing regimes.....	67
1.6	Study hypotheses and conclusions .....	68
Chapter 2	Justification of methods .....	70
2.1	Use of the einhorn rat fracture model .....	70
2.1.1	Species selection .....	70
2.1.2	The incisor absent rat .....	70
2.1.3	Bonnarens and Einhorn Closed fracture model .....	70
2.1.4	Fixation .....	72
2.1.5	Exclusion criteria.....	73
2.2	Fracture repair time course of analysis.....	73
2.2.1	Background on initial endochondral fracture union.....	73
2.2.2	Time points examined to assess initial endochondral repair .....	73
2.2.3	Background on hard callus remodelling during fracture repair .....	73
2.2.4	Time points examined to assess hard callus remodelling.....	74
2.3	Selection of Bisphosphonate dosing regimes.....	74
2.3.1	Background on zoledronic acid.....	74
2.3.2	Single dose compared to weekly dosing of ZA .....	75
2.3.3	Determination of ZA dosage .....	75
2.3.4	Systemic effects of ZA treatment.....	76
2.4	Radiological Analysis.....	77
2.4.1	X-ray .....	77
2.4.2	Dual Energy X-ray Absorptometry (DEXA) .....	78
2.4.3	Quantitative computerized tomography (QCT) .....	78
2.4.4	Micro computerised tomography.....	79
2.5	Histological techniques .....	80
2.5.1	Histomorphometric analysis using BIOQUANT .....	81
2.6	Analysis of serum markers of bone metabolism .....	82
2.7	Mechanical testing of fracture samples .....	82
2.7.1	Background on torsional mechanical testing technique.....	83
2.7.2	Test protocol .....	83
2.7.3	Outcome parameters .....	83
2.8	In vitro studies.....	84
2.8.1	Justification for <i>in vitro</i> examinations .....	84
2.8.2	Primary cell culture technique.....	84
2.9	Dose finding study for the MMP inhibitor MMI270 .....	85
2.9.1	Background on MMP activity during fracture healing.....	85
2.9.2	MMI270, a broad spectrum MMP inhibitor in fracture repair.....	85
2.9.3	MMI270 dose finding study .....	86
2.10	Overall methodological aims.....	86
Chapter 3	Effects of zoledronic acid treatment on endochondral fracture union....	87
3.1	Introduction .....	87
3.2	Study Design .....	89
3.3	Results.....	90
3.3.1	Radiological analysis of fracture union .....	90

## Table of Contents

3.3.2	Quantitative computerized tomographic (QCT) analysis of the fracture callus.....	91
3.3.3	Histological analysis of endochondral ossification .....	95
3.3.3.1	Histomorphometry of cartilage content .....	95
3.3.4	Histological analysis of endochondral ossification during long bone growth .....	96
3.3.4.1	Histomorphometry of growth plate height during ZA influenced growth .....	96
3.4	Discussion .....	98
Chapter 4	Endochondral fracture union in the osteoclast mutant <i>ia/ia</i> rat.....	101
4.1	Introduction .....	101
4.2	Study design .....	102
4.2.1	Phenotype analysis study .....	102
4.2.2	Fracture study .....	103
4.3	Results.....	103
4.3.1	The incisor absent rat bone phenotype.....	103
4.3.1.1	Radiological analysis .....	103
4.3.1.2	Histological analysis.....	106
4.3.1.3	Serum analysis of resorption markers .....	108
4.3.1.4	In vitro primary osteoclast culture analysis .....	109
4.3.2	Confirmation of osteopetrosis in fracture experiment rats .....	115
4.3.2.1	Radiological analysis .....	115
4.3.2.2	Histology .....	116
4.3.3	Analysis of initial fracture repair in <i>ia/ia</i> rats.....	120
4.3.3.1	Radiological analysis .....	120
4.3.3.2	Histological analysis of endochondral ossification .....	124
4.4	Discussion .....	128
4.4.1	Recovery from osteopetrosis in the incisor absent rat.....	128
4.4.2	Assessment of resorption activity in fracture experiment rats.....	131
4.4.3	Endochondral fracture repair in the <i>ia/ia</i> rat.....	132
4.4.4	Endochondral ossification at the growth plate occurs normally in the <i>ia/ia</i> rat. ....	133
4.4.5	Hard callus remodelling in the incisor absent rat fracture callus.....	133
Chapter 5	A single bolus dose of zoledronic acid is superior to weekly dosing, enhancing hard callus size and strength with minimal delays in remodelling after fracture. ....	135
5.1	Introduction .....	135
5.2	Study Design .....	136
5.3	Results.....	137
5.3.1	Radiographic analysis.....	137
5.3.1.1	Fracture union.....	137
5.3.1.2	Quantitative computerised tomography (QCT ) .....	138
5.3.2	Mechanical testing at 6 weeks and 26 weeks.....	143
5.3.3	Hard callus remodelling with ZA treatment .....	147
5.3.3.1	QCT analysis .....	147
5.3.3.2	Histology and histomorphometry .....	148
5.3.3.3	Micro CT analysis .....	149
5.4	Discussion .....	150
Chapter 6	Dose finding study for MMI270 MMP inhibitor in Rats .....	153
6.1	Introduction .....	153
6.2	Study design .....	154
6.2.1	Fracture repair study.....	154

## Table of Contents

6.2.2	Dose finding study .....	155
6.3	Results.....	156
6.3.1	Fracture study.....	156
6.3.1.1	Radiographic union .....	156
6.3.1.2	QCT analysis of fracture callus .....	157
6.3.1.3	Dual energy x-ray absorbitometry (DEXA) scan data of non operated femurs.....	157
6.3.1.4	Histological analysis of fracture healing.....	158
6.3.2	Results from dose finding study for MMI270.....	158
6.3.2.1	Radiographic analysis.....	158
6.3.2.2	Histological analysis.....	159
6.4	Discussion .....	161
Chapter 7	Discussion and Conclusion.....	164
7.1	Endochondral ossification during repair and growth proceeds normally even with bisphosphonate inhibition of osteoclastic resorption. ....	164
7.1.1	Radiological union was achieved regardless of ZA treatment .....	164
7.1.2	Normal rate of endochondral ossification with ZA treatment .....	165
7.1.3	Enhanced net hard callus production with ZA treatment .....	172
7.2	Endochondral fracture union in the osteoclast mutant incisor absent rat. ....	175
7.2.1	The <i>ia/ia</i> rat demonstrates osteopetrosis due to inactive osteoclasts with recovery commencing by 12 weeks of age. ....	175
7.2.2	Experimental <i>ia/ia</i> rats exhibited inactive resorption throughout fracture repair experiments.....	177
7.2.3	Endochondral fracture repair occurs normally in the absence of functionally resorbing osteoclasts in the <i>ia/ia</i> rat. ....	177
7.2.4	Normal Endochondral growth plate height in the <i>ia/ia</i> rat .....	178
7.2.5	Hard callus remodelling is delayed in the <i>ia/ia</i> rat fracture callus. ....	178
7.2.6	Normal endochondral ossification in the <i>ia/ia</i> rat suggests the redundancy of osteoclastic resorption during this initial stage of fracture repair.....	179
7.3	Effects of Bolus compared to continuous ZA treatment on hard callus remodelling .....	181
7.3.1	Enhanced net hard callus production but not callus strength with Weekly ZA treatment compared to bolus.....	181
7.3.2	Superior hard callus remodelling with Bolus ZA compared to Weekly ZA treatment. ....	183
7.3.3	Single Bolus dosing of ZA is preferential to Weekly dosing during the late stage fracture healing.....	184
7.4	High dose levels of the MMP inhibitor MMI270 interferes with normal growth plate endochondral ossification.....	187
7.4.1	Anti-inflammatory dose levels of MMI270 do not interfere with endochondral fracture union. ....	187
7.4.2	High dose MMI270 interferes with normal endochondral growth, lengthening the growth plate of long bones. ....	187
7.4.3	MMI270 can be utilised to inhibit MMP activity and thus elucidate its activities during endochondral ossification .....	188
7.5	Conclusion .....	189
Chapter 8	Appendix.....	190
8.1	Animal Handling and Surgery .....	190
8.1.1	Basic Animal Care .....	190
8.1.2	The Einhorn closed rat fracture model.....	190
8.1.3	Optimisation of the closed rat fracture technique in the incisor absent rat.....	192



## Table of Contents

8.1.3.1	Surgical techniques and modifications.....	192
8.1.3.2	Exclusion criteria.....	193
8.1.4	Dosing Regimes.....	193
8.1.4.1	Bisphosphonate.....	193
8.1.4.2	Matrix metalloproteinase inhibitor.....	194
8.1.5	Sample harvest.....	195
8.2	Radiological Analysis:.....	196
8.2.1	Radiographs.....	196
8.2.2	DEXA.....	197
8.2.3	Quantitative Computerised Tomography (QCT) analysis.....	197
8.2.4	Micro Computerised Tomography ( $\mu$ CT).....	198
8.3	Histology.....	199
8.3.1	Sample preparation.....	199
8.3.2	Un-decalcified histological processing and sectioning (resin): <i>ia/ia</i> rat phenotype samples only.....	200
8.3.3	Decalcified histology sample processing and sectioning (paraffin): Right Femora and posterior left distal femora.....	201
8.3.4	Histological Staining Methods.....	202
8.3.4.1	Paraffin sections:.....	202
8.3.4.2	Resin Section Stains:.....	204
8.3.5	Histomorphometric Analysis.....	205
8.3.5.1	Bioquant software setup for sample group analysis.....	206
8.3.5.2	Fracture callus analysis.....	206
8.3.5.3	Growth plate.....	208
8.3.5.4	Metaphyseal BV/TV analysis.....	209
8.4	Biomechanical testing.....	210
8.4.1	Sample harvest and preparation.....	210
8.4.2	Testing apparatus.....	211
8.4.3	Testing procedure.....	212
8.4.4	Analysis of data.....	212
8.5	In vitro primary osteoclast culture experiments.....	213
8.5.1	RANKL- <i>induce</i> culture in plastic wells.....	213
8.5.1.1	Bone marrow collection.....	213
8.5.1.2	Cell proliferation and differentiation.....	214
8.5.1.3	TRAP staining of osteoclasts.....	215
8.5.1.4	Analysis of osteoclast differentiation.....	215
8.5.2	RANKL- <i>induce</i> osteoclast culture on calcium phosphate discs.....	216
8.5.2.1	Bone marrow collection – as per section 8.5.1.1.....	216
8.5.2.2	Cell proliferation and differentiation.....	216
8.5.2.3	Von Kossa stain on calcium phosphate discs.....	216
8.5.2.4	Analysis of resorption pit formation.....	216
8.5.3	RANKL- <i>induce</i> osteoclast cultures on human bone discs.....	217
8.5.3.1	Bone marrow collection – as per section 8.5.1.1.....	217
8.5.3.2	Cell proliferation and differentiation.....	217
8.5.3.3	Analysis of collagen breakdown products by ELISA.....	217
8.6	Serum analysis of resorption markers.....	218
8.6.1	ELISA assay for CTX.....	218
8.6.1.1	Sample harvest.....	218
8.6.1.2	ELISA method.....	218
8.6.1.3	Data analysis.....	219
8.7	Statistical analysis of data.....	219
References.....		226

## List of Illustrations

<b>Figure 1.1</b>	Schematic depiction of the formation of long bones.	3
<b>Figure 1.2</b>	Histological image of a mammalian growth plate, author's image.	4
<b>Figure 1.3</b>	Histology image of a mammalian growth plate demonstrating mineralisation of cartilage septa, authors image	5
<b>Figure 1.4</b>	Schematic representation of Paracrine regulation of growth plate cartilage maturation.	7
<b>Figure 1.5</b>	Schematic diagram of the role of MMPs in angiogenesis.	11
<b>Figure 1.6</b>	Image of histology section showing the differences in growth plate morphology in WT, MMP-9 KO, MM-13 KO and MMP-9;MMP-13 double KO mice.	13
<b>Figure 1.7</b>	Image of histology section showing localisation of macrophages at the chondro-osseous junction.	16
<b>Figure 1.8</b>	Histology sections demonstrating endochondral fracture healing.	18
<b>Figure 1.9</b>	Schematic drawing of vascular invasion during endochondral ossification in healing fractures.	23
<b>Figure 1.10</b>	Diagram of the two main stages of osteoclastic resorption, adhesion and cytodifferentiation and subsequent resorption.	28
<b>Figure 1.11</b>	Depiction of the stages leading to bone resorption.	50
<b>Figure 1.12</b>	Generic formula for a bisphosphonate	56
<b>Table 1.1</b>	Outlines the approximate relative potencies (to Etidronate) of bisphosphonates in inhibition of metaphyseal bone resorption in vivo	57
<b>Figure 1.13</b>	Effect of incadronate on rat fracture healing.	62
<b>Figure 1.14</b>	Effect of incadronate on rat fracture healing.	63
<b>Figure 1.15</b>	The chemical structure of Zoledronic Acid.	66
<b>Figure 1.16</b>	The effects of various bisphosphonates on MMP activities, activation, production, and malignant cell invasion	67
<b>Figure 2.1</b>	Image of closed fracture apparatus sketch from Bonnarens and Einhorn used to develop apparatus used in this study.	71
<b>Figure 2.2</b>	Image of closed fracture apparatus used in experiments.	72
<b>Figure 2.3</b>	Comparison of resolution and detail obtained from QCT and $\mu$ CT scans.	79
<b>Table 3.1</b>	Sample numbers harvested for each treatment groups at 1, 2, 4 and 6 weeks post fracture.	89
<b>Table 3.2</b>	X-ray grading of samples at 2, 4 and 6 weeks post fracture	90
<b>Figure 3.1</b>	Representative X-rays at each time point examined for each treatment group.	91
<b>Figure 3.2</b>	Bar chart of Mean values for Callus BMC for all treatment groups at 2, 4 and 6 weeks post fracture.	92
<b>Table 3.3</b>	Quantitative computerise tomography data for fractured femurs for all treatment groups at 2, 4 and 6 weeks post fracture.	93
<b>Figure 3.3</b>	Bar chart of mean values for callus volume for all treatment groups at 2, 4 and 6 weeks post fracture.	94

## List of Illustrations

<b>Figure 3.4</b>	Bar Chart of mean values for percentage callus vascular bone content for all treatment groups at 2, 4 and 6 weeks post fracture.	95
<b>Figure 3.5</b>	Representative sections from Saline, Bolus LD and HD ZA and Weekly LD and HD ZA at 2, 4 and 6 weeks post fracture.	96
<b>Figure 3.6</b>	Mean values for femoral growth plate height for all treatment groups at 2, 4 and 6 week post fracture time points.	97
<b>Figure 3.7</b>	Representative sections of growth plate from distal femurs of each treatment group at each time point examined author's images.	98
<b>Figure 4.1</b>	Bar chart demonstrating mean femur length in <i>ia/ia</i> and <i>wt/het</i> rats.	104
<b>Figure 4.2</b>	Representative X-ray images of tibiae at each time point examined for phenotype analysis.	105
<b>Figure 4.3</b>	Bar charts of mean values for proximal tibia BMC and BMD for <i>ia/ia</i> and <i>wt/het</i> rats from DEXA scan analysis.	106
<b>Figure 4.4</b>	Bar charts of mean proximal and distal metaphyseal BV/TV.	107
<b>Figure 4.5</b>	Representative Von Kossa stained sections at 3, 5, 7, 9, 12, and 20 weeks of age used for BV/TV analysis.	108
<b>Figure 4.6</b>	Bar chart of mean values of serum CTX levels in <i>ia/ia</i> and <i>wt/het</i> rats at each time point examined.	109
<b>Figure 4.7a</b>	Representative images of osteoclast differentiation and resorption assays at 5 and 9 weeks of age.	111
<b>Figure 4.7b</b>	Representative images of osteoclast differentiation and resorption assays at 12 and 20 weeks of age.	111
<b>Figure 4.8a</b>	Bar chart of mean osteoclast number per region of interest (ROI) in <i>wt/het</i> and <i>ia/ia</i> cell cultures at 5, 9, 12 and 20 weeks of age.	112
<b>Figure 4.8b</b>	Bar chart of mean percent area of calcium phosphate disc resorbed for both <i>wt/het</i> and <i>ia/ia</i> cell cultures at 5, 9, 12 and 20 weeks of age.	113
<b>Table 4.1</b>	Data values for Helical peptide concentrations from human bone disc culture experiment.	114
<b>Figure 4.9</b>	Image of TRAP positive cells on human bone chip discs in culture after media removed for analysis.	114
<b>Figure 4.10</b>	Representative x-ray images of Proximal tibia from <i>wt/het</i> and <i>ia/ia</i> samples from rats at the 1, 2, and 3 week time points of the fracture experiments.	115
<b>Figure 4.11</b>	Bar charts of mean proximal tibial metaphyseal BMC measured by DEXA in <i>wt/het</i> and <i>ia/ia</i> rats from fracture experiments at 1, 2, and 3 weeks post fracture.	116
<b>Table 4.2</b>	Data generated from histomorphometric analysis of proximal tibial metaphysis in growing <i>ia/ia</i> and <i>wt/het</i> rats.	117
<b>Figure 4.12</b>	Bar charts of mean values for tibial metaphyseal BV/TV of fracture samples for both <i>ia/ia</i> and <i>wt/het</i> genotypes at 1, 2 and 3 weeks post fracture.	118
<b>Figure 4.13</b>	Representative proximal tibia Von Kossa stained sections of <i>wt/het</i> and <i>ia/ia</i> rat samples at 1, 2, and 3 weeks post fracture.	118
<b>Figure 4.14</b>	Bar charts of mean values for tibial metaphyseal trabeculae thickness of fracture samples for both <i>ia/ia</i> and <i>wt/het</i> genotypes at 1, 2 and 3 weeks post fracture.	119

## List of Illustrations

<b>Figure 4.15</b>	Bar charts of mean values for tibial metaphyseal trabecular number of fracture samples for both <i>ia/ia</i> and <i>wt/het</i> genotypes at 1, 2 and 3 weeks post fracture.	119
<b>Figure 4.16</b>	Bar charts of percent union rates of both <i>wt/het</i> and <i>ia/ia</i> rats at 1, 2, and 3 weeks post fracture as assessed radiologically.	120
<b>Figure 4.17</b>	Representative cross sectional QCT scan images of the central region of the fracture site of both <i>wt/het</i> and <i>ia/ia</i> fracture samples at 1, 2 and 3 weeks post fracture.	122
<b>Table 4.3</b>	Data generated from quantitative computerised tomography (QCT) scans of operated and non-operated femora of <i>ia/ia</i> and <i>wt/het</i> rats.	123
<b>Figure 4.18</b>	Representative sections of <i>wt/het</i> and <i>ia/ia</i> samples at each time point examined demonstrating normal endochondral ossification.	125
<b>Figure 4.19</b>	Bar chart of mean percent of callus containing vascular bone tissue for <i>wt/het</i> and <i>ia/ia</i> samples at 1, 2 and 3 weeks post fracture.	126
<b>Figure 4.20</b>	Bar charts of mean total callus area and avascular callus area for both <i>wt/het</i> and <i>ia/ia</i> samples at 1, 2 and 3 weeks post fracture.	126
<b>Figure 4.21</b>	Bar chart of mean growth plate height from the proximal tibia for oth <i>wt/het</i> and <i>ia/ia</i> samples at the 1, 2 and 3 weeks post fracture time points.	127
<b>Figure 4.22</b>	Representative sections of proximal tibial growth plates from <i>wt/het</i> and <i>ia/ia</i> samples at 1, 2 and 3 weeks post fracture.	128
<b>Table 5.1</b>	Treatment groups and sample allocations.	137
<b>Table 5.2</b>	The number of samples united or not united per treatment group at 6, 12 and 26 weeks post fracture.	138
<b>Figure 5.1</b>	Representative x-ray images of samples from each treatment group at 6 weeks demonstrating complete union at this stage.	138
<b>Figure 5.2</b>	Representative cross sectional images from QCT scans at the central region of the fracture site for each treatment group at 4, 6, 12 and 26 weeks post fracture.	139
<b>Table 5.3</b>	Mean values for data generated by QCT for bone mineral content (BMC), bone volume (Volume) and polar moment of inertia.	140
<b>Figure 5.3a</b>	Bar chart showing mean callus BMC for all treatment groups from 2 – 26 weeks post fracture.	141
<b>Figure 5.3b</b>	Bar chart showing mean callus bone volume for all treatment groups from 2 – 26 weeks post fracture.	141
<b>Figure 5.4a</b>	Bar chart of mean fracture callus peak torque to failure for each treatment group at 6 and 26 weeks post fracture.	143
<b>Table 5.4</b>	Data generated from mechanical testing of both operated and non-operated femurs at 6 and 26 weeks post fracture. Data is presented at mean (standard deviation).	144
<b>Figure 5.4b</b>	Bar chart of mean values for fracture callus peak stress for each treatment group at 6 and 26 weeks post fracture.	145
<b>Figure 5.4c</b>	Bar chart of mean values for fracture callus shear modulus for each treatment groups at 6 and 26 weeks post fracture.	146
<b>Figure 5.5</b>	Bar charts of mean values for percentage of callus neo-cortical bone and primary callus area at 6, 12 and 26 weeks post fracture for each treatment group.	147

## List of Illustrations

<b>Figure 5.6</b>	Representative images of sections of samples from each treatment group at 6, 12 and 26 weeks.	148
<b>Figure 5.7</b>	Representative 3D cross sectional reconstruction images from the central fracture region generated from micro CT scans at 26 weeks for each treatment group.	149
<b>Table 6.1</b>	Union rates in MMI270 and vehicle groups as determined from radiographs.	155
<b>Figure 6.1</b>	Representative X-ray images of fractured femora from each treatment group at each harvest time point.	155
<b>Table 6.2</b>	Data generated from QCT scans of operated femurs for bone mineral content (BMC), bone mineral density (BMD), bone volume (Volume) and polar moment of inertia.	156
<b>Table 6.3</b>	Data generated from DEXA scans of non-operated femurs	156
<b>Figure 6.2</b>	Representative X-ray images of proximal tibia from each treatment group from dose finding study after 4 weeks of dosing with MMI270.	157
<b>Figure 6.3a</b>	Representative images of histological sections of proximal tibia stained with Saffranin O, Light Green for each treatment group.	158
<b>Figure 6.3b</b>	Representative images of histological sections from the proximal tibia stained with Saffranin O, Light Green for control and high dose (120mg/kg) SC.	159
<b>Figure 6.3c</b>	Representative images of histological sections of proximal tibial growth plates stained with Von Kossa and Toluidine Blue for control and high dose (120mg/kg) MMI270 SC.	160
<b>Figure 7.1</b>	Histological images of TRAP positive cells localised at the chondro-osseous junction.	165
<b>Figure 7.2</b>	Image of histology section showing localisation of macrophages at the chondro-osseous junction.	166
<b>Figure 7.3a</b>	Histological images of a lack of TRAP positive cells in op/op mouse metaphyseal bone.	168
<b>Figure 7.3b</b>	Histology sections of the chondro-osseous junction of op/op mice (B and F) compared to their normal litter mates (A and E).	169
<b>Figure 7.3c</b>	X-ray images and histology sections of endochondral fracture repair of op/op mice (G, H, I and K).	170
<b>Figure 8.1</b>	Surgical insertion of the intramedullary k-wire.	190
<b>Figure 8.2</b>	Post surgery x-ray demonstrating correct placement of intramedullary k-wire and creation of a clean transverse mid diaphyseal fracture using the apparatus.	190
<b>Table 8.1</b>	Post operative grading by radiographs.	191
<b>Table 8.2</b>	ZA treatment groups.	193
<b>Figure 8.3</b>	Chemical formula and supplier details for zoledronic acid as used in this investigation.	193
<b>Figure 8.4</b>	Chemical formula for the MMP inhibitor MMI270 used in this investigation.	194
<b>Figure 8.5</b>	Radiograph examples of fracture calluses.	195
<b>Figure 8.6</b>	Example of a cross sectional CT scan slice image generated from Stratec QCT scan data using Scion image.	197
<b>Figure 8.7</b>	Images of bone tissue sections stained with a) H&E, b) Saffranin O/Light Green, c) Alcian Blue/Sirius Red, and d) Von Kossa.	204

## List of Illustrations

<b>Figure 8.8</b>	Example of image analysis using Bioquant to determine the area of each callus containing vascular bone tissue.	206
<b>Figure 8.9</b>	Example of image analysis using Bioquant to determine the area of each callus containing remodelled neo-cortical bone.	207
<b>Figure 8.10</b>	Example of image analysis using Bioquant to determine the average growth plate height for ZA treated Wistar rats and <i>ia/ia</i> phenotype samples.	208
<b>Figure 8.11</b>	Example of image analysis using Bioquant to determine the metaphyseal BV/TV.	209
<b>Figure 8.12</b>	A close up photograph of the ELF testing apparatus testing a fracture sample in torsion.	210

### Abbreviations

ALN	Alendronate
$\alpha\beta 3$	Alpha V beta 3
ANOVA	Analysis of Variance
ATP	Adenosine triphosphate
bFGF	Basic fibroblastic growth factor
BMC	Bone mineral content
BMD	Bone mineral density
BMU	Bone remodelling unit
BP	Bisphosphonate
BPs	Bisphosphonates
BV/TV	Bone volume/ total volume (%)
CIC-7	Chlorine channel - 7
Col X	Collagen type X
CSF-1	Colony stimulating factor-1
CMC	Carboxymethyl cellulose
CTX	C-terminal telopeptide cross-links
DEPC	Diethylpolycarbonate
DEXA	Dual energy X-ray Absorbtiometry
DMSO	Dimethyl sulfoxide
ECM	Extracellular matrix
EDTA	Ethlyenediaminetetra Acetic Acid (disodium salt)
ELISA	Enzyme-linked immunosorbent assay
FBS	Foetal Bovine Serum
FPPS	Farensyl diphosphate synthase

## Abbreviations

GTP	Guanosine triphosphate
HD	High dose
HS	Heperan sulfate
HSPG	Heperan sulfate proteoglycans
<i>ia/ia</i>	Incisor absent rat
ICTP	Cross-linked carboxyterminal telopeptide of type I collagen
Ihh	Indian hedgehog
IV	Intravenous
KO	Knockout
LD	Low dose
M-CSF	Macrophage colony stimulating factor
$\mu$ CT	Micro computerised tomography.
Mins	Minutes
MMA	Methylmethacrylate
MMP	Matrix metalloproteinase
MMP-9	Matrix metalloproteinase 9
MMP-13	Matrix metalloproteinase 13
mRNA	Messenger ribonucleic acid
N-BP	Nitrogen containing Bisphosphonate
NLM	Normal littermate
Oc	Osteocalcin
<i>oc/oc</i>	osteosclerotic mouse
OI	Osteogenesis Imperfecta
<i>op/op</i>	osteopetrotic mouse
OPG	Osteoprotegerin



## Abbreviations

OPN	Osteopontin
OVX	Ovariectomised
PBS	Phosphate buffered saline
P-C-P	Phosphorous-carbon-phosphorous
PCNA	Proliferating cell nuclear antigen
PECAM	Proliferating endothelial cell adhesion marker
PFA	Paraformaldehyde
PLGA	Poly L-lactide-co-glycolide
Ptc	Patched 1
PTH	Parathyroid hormone
PTHrP	Parathyroid hormone related protein
QCT	Quantitative computerised tomography
RANK	Receptor-activator of nuclear factor kappa beta
RANKL	Receptor-activator of nuclear factor kappa beta ligand
RNA	Ribonucleic acid
ROI	Region of Interest
RT	Room temperature
SC	Subcutaneous
SD	Standard deviation
SE	Standard error
Tb.N	Trabecular number
Tb.th	Trabecular thickness
TGF $\beta$	Transforming growth factor beta
tl/tl	Toothless rat
TRAP	Tartrate resistant acid phosphatase

## Abbreviations

VEGF	Vascular endothelial growth factor
wt/het	wild type / heterozygous
ZA	Zoledronic Acid

## Abstract

Bisphosphonates (BPs) are the most common treatment for osteoporosis, due to their powerful ability to inhibit osteoclastic bone resorption. They are also being investigated to augment callus production during fracture healing, however, concerns exist as to the effects of BPs during both initial fracture union and hard callus remodelling. Endochondral ossification during fracture repair is a critical process leading to initial union, and is assumed to be dependent on osteoclast function. Hard callus remodelling, known to be dependent on osteoclast function, is important to the completion of bone repair.

The role of osteoclasts during initial endochondral fracture union was investigated using the BP zoledronic acid (ZA) and in a genetic model of osteoclast inactivity, the incisor absent (*ia/ia*) rat. In addition, the effect of differing ZA treatment regimes on hard callus remodelling was investigated using both Bolus and Weekly ZA dosing. A Bolus of 0.1mg/kg ZA or 5 Weekly doses of 0.02mg/kg ZA or Saline were administered commencing 1 week post surgery in a rat femoral fracture model. Femoral fractures were also produced in *ia/ia* rats. Examinations were performed up to initial union and throughout callus remodelling.

ZA treatment did not alter the rate of endochondral fracture union. All fractures united by 6 weeks, with no difference in the percentage of cartilaginous callus between treatment groups at any time point. Fracture union was achieved by 3 weeks in both *ia/ia* and control rats, again with no difference in the percentage of cartilaginous callus.

In contrast, marked differences in hard callus were evident in the ZA treated groups. ZA increased callus bone mineral content, volume and importantly increased callus strength. Bolus ZA treatment did not delay the commencement of hard callus remodelling at 4 weeks post fracture, whereas this was delayed in the Weekly ZA group. By 12 and 26 weeks Bolus ZA had the same callus content of remodelled neo-cortical bone as Saline, however Weekly ZA had significantly less than saline at these times. These extensive delays in hard callus remodelling with Weekly ZA dosing produced a fracture callus of inferior material properties.

In conclusion, neither ZA treatment nor the absence of active osteoclasts in *ia/ia* rats delayed endochondral fracture union. Thus, this study confirms the redundancy of osteoclasts in this process. Bolus ZA treatment was superior to Weekly ZA dosing; hard callus remodelling proceeded, producing a strong fracture callus with improved material properties. This study supports the use of less frequent ZA doses during fracture repair.